Skip to main content

Table 4 Subgroup analysis based on different standard

From: The value of kidney injury molecule 1 in predicting acute kidney injury in adult patients: a systematic review and Bayesian meta-analysis

Studies

Sensitivity (95% CrI)

Specificity (95% CrI)

+ LR (95% CrI)

− LR (95% CrI)

DOR (95% CrI)

RD (95% CrI)

AUC (95% CrI)

All studies (14)

0.74 (0.62–0.84)

0.84 (0.76–0.90)

4.58 (2.78–9.47)

0.34 (0.23–0.46)

15.22 (6.74–42.20)

0.55 (0.43–0.70)

0.62 (0.41–0.76)

Study design

 Prospective (9)

0.65 (0.51–0.81)

0.76 (0.70–0.82)

2.75 (2.47–3.21)

0.47 (0.24–0.62)

6.68 (4.00–13.18)

0.41 (0.30–0.56)

0.73 (0.67–0.85)

 Non-prospective (5)

0.82 (0.66–0.92)

0.91 (0.74–0.99)

9.36 (2.48–24.05)

0.17 (0.07–0.27)

57.21 (16.26–134.38)

0.67 (0.53–0.78)

0.69 (0.30–0.95)

Blinding or not

 Blinding (5)

0.68 (0.43–0.89)

0.76 (0.68–0.82)

2.97 (2.49–3.53)

0.37 (0.24–0.55)

9.18 (4.62–14.49)

0.48 (0.35–0.58)

0.76 (0.64–0.82)

 Non-blinding (9)

0.77 (0.65–0.88)

0.88 (0.78–0.96)

6.29 (3.89–12.03)

0.25 (0.17–0.32)

28.64 (12.26–72.31)

0.65 (0.55–0.77)

0.64 (0.24–0.89)

Population settings

 CPB surgery (4)

0.73 (0.45–0.93)

0.77 (0.62–0.90)

4.06 (2.10–7.53)

0.41 (0.31–0.64)

11.75 (3.50–23.51)

0.47 (0.27–0.61)

0.75 (0.49–0.90)

 Emergency and critical patients (4)

0.62 (0.365–0.857)

0.79 (0.66–0.91)

3.79 (1.00–6.96)

0.44 (0.22–0.72)

13.25 (2.82–31.69)

0.45 (0.22–0.68)

0.61 (0.44–0.80)

 Others (6)

0.80 (0.66–0.91)

0.89 (0.75–0.97)

7.73 (5.28–13.56)

0.18 (0.16–0.22)

44.44 (24.23–85.74)

0.71 (0.66–0.79)

0.75 (0.54–0.91)

Assay method

 ELISA (12)

0.78 (0.68–0.88)

0.85 (0.75–0.92)

5.59 (3.05–10.18)

0.26 (0.15–0.34)

25.04 (10.33–65.82)

0.63 (0.52–0.77)

0.66 (0.41–0.89)

 Non-ELISA (2)

0.45 (0.27–0.65)

0.80 (0.72–0.86)

2.43 (2.35–2.51)

0.65 (0.62–0.67)

3.78 (3.50–4.05)

0.28 (0.26–0.30)

0.55 (0.53–0.57)

  1. CrI credible interval